Clinical manifestations of cutaneous lupus erythematosus.
Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune disease with a broad spectrum of clinical manifestations and a variable course. In numerous investigations, it has been shown that exogenous factors, such as UV-light and drugs, can induce this disease. However, not all clinical aspects can be explained and therefore, the pathogenesis of CLE is currently under extensive research. The various cutaneous manifestations of LE are divided into LE-nonspecific and LE-specific skin disease based on histologic criteria. LE-nonspecific manifestations are mostly associated with systemic LE but can also occur in other diseases and include particularly vascular skin lesions such as pe-riungual telangiectases. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). The subdivision of these subtypes with different prognosis and course is supported by genetic, clinical, histologic, and immunoserologic findings. The subtypes of CLE require a specific morphological and clinical analysis, which is described in the first part of this review. In the second part of this review, further diagnostic procedures and therapeutic strategies in patients with CLE are discussed.
Kuhn
Annegret
A
Department of Dermatology, Düsseldorf University Clinic, Düsseldorf, Germany. kuhnan@uni-duesseldorf.de
Sticherling
Michael
M
Bonsmann
Gisela
G
D000974:Antibodies, Antinuclear / Q000097:blood; D003937:Diagnosis, Differential; D005260:Female; D006327:Heart Block / Q000151:congenital / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D008178:Lupus Erythematosus, Cutaneous / Q000145:classification / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D011247:Pregnancy; D011379:Prognosis; D012307:Risk Factors; D012867:Skin / Q000473:pathology
D000974:Antibodies, Antinuclear; C035356:SS-A antibodies; C035357:SS-B antibodies